72 CHAPTER 3 34. Davies H, Glodzik D, Morganella S, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine 2017;23:517-+. 35. Nguyen L, J WMM, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun 2020;11:5584. 36. Van De Haar J, Hoes LR, Roepman P, Cuppen E, Wessels LF, Voest EE. Genomic evolution of metastatic tumours under therapeutic pressure. Ann Oncol 2020;31:S274-S. 37. Shimelis H, Mesman RLS, Von Nicolai C, et al. BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research 2017;77:2789-99. 38. Naipal KAT, Verkaik NS, Ameziane N, et al. Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research 2014;20:4816-26. 39. Fukumoto T, Zhu HR, Karakashev S, et al. The N6-Methylation of Adenosine (M6a) in Fzd10 Mrna Contributes to Resistance to Parp Inhibitor. Clinical Cancer Research 2019;25:204-. 40. Angus L, Smid M, Wilting SM, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet 2019;51:1450-+. 41. Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013;19:3693-702. 42. Brunello E, Brunelli M, Bogina G, et al. FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. J Exp Clin Cancer Res 2012;31:103. 43. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085-94. 44. Wang L, Zhang P, Molkentine DP, et al. TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects. Oncogene 2017;36:820-8. 45. Molkentine JM, Molkentine DP, Bridges KA, et al. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol 2020. 46. Liu L, Zhou W, Cheng CT, et al. TGFbeta induces “BRCAness” and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. Mol Cancer Res 2014;12:1597-609. 47. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. Plos Med 2006;3:1865-76. 48. Sun CY, Fang Y, Yin J, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine 2017;9. 49. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020. 50. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
RkJQdWJsaXNoZXIy MTk4NDMw